Subject: Treating Pill Addiction With Pot and Implants

SCV Client Spotlight
Treating Pill Addiction With Pot and Implants
Hot Stock to WatchHot Stock to Watch

Company: BioCorRx Inc. (OTCQB: BICX)


Price: 0.18

Change (%): - 0.008 (4.26)

Volume: 69,919
BICX Chart

Treating Pill Addiction With Pot and Implants

NEW YORK (MainStreet) - Although the Drug Quality and Security Act was passed by President Obama to address the meningitis outbreak and lack of sterilization at a compounding pharmacy in New England, it may pave the way to improve the quality, potency and purity of cannabis-based products. In addition, this measure could provide the impetus for pharmaceutical companies to enter the medical marijuana market.

“Good manufacturing practices is what this is all about,” said Joseph Friedman, director of marketing and business development for Mark Drugs, a compounding pharmacy in Lincolnshire, Illinois. “All compounding pharmacies must either have a manufacturing license to produce mass quantities of a particular compounded medication or must have on record the individual patient names and demographics for each dose or preparation of a compounded pharmaceutical.”

Using an implant as the delivery system for drugs such as Naltrexone is an approved process under current compounding laws when prescribed by a doctor.

“Since the implant is surgically implanted, it must be completely sterilized first,” said Brady Granier, chief operating officer of BioCorRx (BICX). “Any compound that is implanted or injected needs to be free of contamination and the Drug Quality and Security Act will make sure that these compounds are safe for use if all compounding pharmacies follow the rules.”

Continue Reading

Like Us on FacebookFollow Us on Twitter

SmallCapVoice (SCV) is an electronic publication. Information sources for our profiles include, but are not limited to, online research, member suggestions, magazines, newspapers, analyst suggestions, information provided by the profiled company, press releases and similar sources. This communication is not an offer to sell or a recommendation that you buy or sell any security. SCV holds no securities licenses and is not qualified to provide investment advice. We are compensated for these advertisements by the profiled companies. You should not use this newsletter as the sole basis for any investment decision. While all investments involve risk, microcap stocks are among the most risky. Many microcap companies have no proven track record. You should only invest in microcap companies if you can afford to lose your entire investment. You should consult a qualified, licensed financial advisor or stock broker before making any decisions to invest in the securities of any company that is described in these profiles. These profiles are paid advertisements. Although we have a reasonable belief that the information in each profile is accurate, we cannot guarantee that the information is accurate. It is important for you to verify all information by your own independent research. You are receiving this message because you have agreed to receive emails from You may opt out of our distribution list at any time by clicking on the “unsubscribe” link below. Link to full disclosure about compensation paid to, Inc. by companies featured on our website or in our e-mail communications.

About Penny Stocks